Breaking News Instant updates and real-time market news.

INFY

Infosys

$14.83 /

-0.16 (-1.07%)

05:05
11/20/20
11/20
05:05
11/20/20
05:05

Infosys, the ATP extend partnership three more years

Infosys and the ATP have announced the renewal of their partnership for a further three years. The agreement will see Infosys continue as global technology services partner and digital innovationpartner of the ATP, through 2023. As the technology partner of the ATP since 2015, Infosys has supported ATP's development of digital assets and infrastructure, including ATP PlayerZone, ATP Stats Leaderboards, ATP Second Screen, and the ATP app. Through the extended partnership, Infosys will continue to develop and accelerate innovations in advanced technologies.

INFY Infosys
$14.83 /

-0.16 (-1.07%)

10/15/20 BMO Capital
Infosys price target raised to $18 from $13 at BMO Capital
10/15/20 Baird
Infosys downgraded to Underperform from Neutral at Baird
10/06/20 ICICI Securities
Infosys upgraded to Buy from Hold at ICICI Securities
07/16/20 Nomura
Infosys upgraded to Buy from Neutral at Nomura Instinet

TODAY'S FREE FLY STORIES

General news
Japan consumer prices stopped falling » 02:05
09/24/21
09/24
02:05
09/24/21
02:05
$ECON

Economic Data

/

+

Japan consumer prices…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
U.S. new home sales preview » 02:05
09/24/21
09/24
02:05
09/24/21
02:05
$ECON

Economic Data

/

+

U.S. new home sales…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Asian Market Update: » 01:55
09/24/21
09/24
01:55
09/24/21
01:55
$ECON

Economic Data

/

+

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

Syndicate
Cue Health 12.5M share IPO priced at $16.00 » 21:16
09/23/21
09/23
21:16
09/23/21
21:16
HLTH

Cue Health

/

+

The deal priced at…

The deal priced at midpoint of $15.00-$17.00 target range. Goldman Sachs, Morgan Stanley and Cowen are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 24
    Sep
HLTH Cue Health
/

+

Initiation
Tenet Healthcare initiated with a Neutral at UBS » 21:14
09/23/21
09/23
21:14
09/23/21
21:14
THC

Tenet Healthcare

$72.74 /

-0.515 (-0.70%)

UBS analyst Andrew Mok…

UBS analyst Andrew Mok initiated coverage of Tenet Healthcare with a Neutral rating and $83 price target. The stock's valuation is being anchored by hospital business multiple, the analyst tells investors in a research note. Mok adds that Tenet's target to reach 50% ambulatory EBITDA by 2023 requires significant M&A, though the expected Conifer spin "could change that".

ShowHide Related Items >><<
THC Tenet Healthcare
$72.74 /

-0.515 (-0.70%)

THC Tenet Healthcare
$72.74 /

-0.515 (-0.70%)

09/23/21 UBS
Tenet Healthcare initiated with a Neutral at UBS
08/12/21 Barclays
Tenet Healthcare assumed at Overweight from Equal Weight at Barclays
07/23/21
Fly Intel: Top five analyst initiations
07/23/21 RBC Capital
Tenet Healthcare price target raised to $83 from $78 at RBC Capital
THC Tenet Healthcare
$72.74 /

-0.515 (-0.70%)

THC Tenet Healthcare
$72.74 /

-0.515 (-0.70%)

THC Tenet Healthcare
$72.74 /

-0.515 (-0.70%)

Initiation
Community Health initiated with a Neutral at UBS » 21:12
09/23/21
09/23
21:12
09/23/21
21:12
CYH

Community Health

$11.26 /

+0.08 (+0.72%)

UBS analyst Andrew Mok…

UBS analyst Andrew Mok initiated coverage of Community Health with a Neutral rating and $12.50 price target. The company has done a "nice job" re-positioning its hospital portfolio and improved its EBITDA margins over the last three years, the analyst tells investors in a research note. Mok adds however that the resurgence of COVID cases has caused Community Health's COVID inpatient census to surpass prior peaks, which has led to a 15% decline in its non-COVID census in August.

ShowHide Related Items >><<
CYH Community Health
$11.26 /

+0.08 (+0.72%)

CYH Community Health
$11.26 /

+0.08 (+0.72%)

09/23/21 UBS
Community Health initiated with a Neutral at UBS
08/23/21 Truist
Community Health price target lowered to $14 from $17 at Truist
08/03/21 Barclays
Community Health price target raised to $10 from $6 at Barclays
07/09/21 Seaport Global
Seaport initiates five in Healthcare Facilities and Services with three Buys
CYH Community Health
$11.26 /

+0.08 (+0.72%)

CYH Community Health
$11.26 /

+0.08 (+0.72%)

CYH Community Health
$11.26 /

+0.08 (+0.72%)

CYH Community Health
$11.26 /

+0.08 (+0.72%)

Initiation
LHC Group initiated with a Neutral at UBS » 21:09
09/23/21
09/23
21:09
09/23/21
21:09
LHCG

LHC Group

$160.85 /

-3.63 (-2.21%)

UBS analyst Andrew Mok…

UBS analyst Andrew Mok initiated coverage of LHC Group with a Neutral rating and $170 price target. The analyst states that the company's positive growth is being balanced by near-term risk factors, adding that while the Street is overlooking 2022 earnings contribution from accelerating acquisitions, given the structural headwinds in the hospice industry, a multiple expansion is "difficult to see".

ShowHide Related Items >><<
LHCG LHC Group
$160.85 /

-3.63 (-2.21%)

LHCG LHC Group
$160.85 /

-3.63 (-2.21%)

09/23/21 UBS
LHC Group initiated with a Neutral at UBS
09/22/21 Deutsche Bank
LHC Group price target lowered to $245 from $260 at Deutsche Bank
09/09/21 Cowen
LHC Group initiated with an Outperform at Cowen
08/12/21 Barclays
LHC Group assumed at Equal Weight from Overweight at Barclays
LHCG LHC Group
$160.85 /

-3.63 (-2.21%)

LHCG LHC Group
$160.85 /

-3.63 (-2.21%)

Initiation
Amedisys initiated with a Sell at UBS » 21:06
09/23/21
09/23
21:06
09/23/21
21:06
AMED

Amedisys

$161.41 /

-2.7 (-1.65%)

UBS analyst Andrew Mok…

UBS analyst Andrew Mok initiated coverage of Amedisys with a Sell rating and $150 price target as part of a broader research note on healthcare providers. The analyst warns that the hospice segment carries elevated risk and uncertainty over the near-term due to sensitivity to COVID surges and COVID-driven excess mortality. Mok adds that he expects negative revisions to Street estimates heading into 2022 to drive a near-term de-rating in Amedisys multiple.

ShowHide Related Items >><<
AMED Amedisys
$161.41 /

-2.7 (-1.65%)

AMED Amedisys
$161.41 /

-2.7 (-1.65%)

09/23/21 UBS
Amedisys initiated with a Sell at UBS
09/09/21 Cowen
Amedisys initiated with a Market Perform at Cowen
08/11/21 Credit Suisse
Amedisys price target lowered to $250 from $330 at Credit Suisse
AMED Amedisys
$161.41 /

-2.7 (-1.65%)

AMED Amedisys
$161.41 /

-2.7 (-1.65%)

Initiation
Universal Health initiated with a Sell at UBS » 21:05
09/23/21
09/23
21:05
09/23/21
21:05
UHS

Universal Health

$144.44 /

-1.16 (-0.80%)

UBS analyst Andrew Mok…

UBS analyst Andrew Mok initiated coverage of Universal Health with a Sell rating and $136 price target as part of a broader research note on healthcare providers. His negative view on the stock is driven by limited organic EBITDA growth, the analyst tells investors in a research note, adding that his 2022 and 2023 EBITDA forecasts that are 4% and 5% below Street estimates due "structural differences" in behavioral demand relative to Acacia Healthcare (ACHC) and no meaningful positive growth catalysts.

ShowHide Related Items >><<
UHS Universal Health
$144.44 /

-1.16 (-0.80%)

UHS Universal Health
$144.44 /

-1.16 (-0.80%)

09/23/21 UBS
Universal Health initiated with a Sell at UBS
09/09/21 Cowen
Universal Health's behavioral unit suffers from execution stumbles, says Cowen
09/09/21 Cowen
Universal Health initiated with an Outperform at Cowen
09/08/21
Fly Intel: Top five analyst downgrades
UHS Universal Health
$144.44 /

-1.16 (-0.80%)

UHS Universal Health
$144.44 /

-1.16 (-0.80%)

UHS Universal Health
$144.44 /

-1.16 (-0.80%)

UHS Universal Health
$144.44 /

-1.16 (-0.80%)

Initiation
HCA Healthcare initiated with Buy, $312 target at UBS » 21:00
09/23/21
09/23
21:00
09/23/21
21:00
HCA

HCA Healthcare

$255.53 /

-2.7 (-1.05%)

UBS analyst Andrew Mok…

UBS analyst Andrew Mok initiated coverage of HCA Healthcare with a Buy rating and $312 price target. Thea analyst believes HCA is in a positive earnings revision cycle with strong demand, market share gains and free cash flow likely to drive EBITDA above consensus 2022 estimates.

ShowHide Related Items >><<
HCA HCA Healthcare
$255.53 /

-2.7 (-1.05%)

HCA HCA Healthcare
$255.53 /

-2.7 (-1.05%)

09/23/21 UBS
HCA Healthcare initiated with a Buy at UBS
09/09/21 Cowen
HCA's EBITDA outperformance remains underestimated, says Cowen
09/09/21 Cowen
HCA Healthcare initiated with an Outperform at Cowen
08/12/21 Barclays
HCA Healthcare assumed at Equal Weight from Overweight at Barclays
HCA HCA Healthcare
$255.53 /

-2.7 (-1.05%)

HCA HCA Healthcare
$255.53 /

-2.7 (-1.05%)

HCA HCA Healthcare
$255.53 /

-2.7 (-1.05%)

HCA HCA Healthcare
$255.53 /

-2.7 (-1.05%)

Initiation
Acadia Healthcare initiated with Buy, $81 target at UBS » 20:58
09/23/21
09/23
20:58
09/23/21
20:58
ACHC

Acadia Healthcare

$65.15 /

-0.33 (-0.50%)

UBS analyst Andrew Mok…

UBS analyst Andrew Mok initiated coverage of Acadia Healthcare with a Buy rating and $81 price target. The analyst has conviction in the company's ability to achieve 10% EBITDA growth target through 2025. This will be driven by Acadia's "industry leading" organic volume growth and $150M of balanced EBITDA contribution from growth initiatives, Mok tells investors in a research note.

ShowHide Related Items >><<
ACHC Acadia Healthcare
$65.15 /

-0.33 (-0.50%)

ACHC Acadia Healthcare
$65.15 /

-0.33 (-0.50%)

09/23/21 UBS
Acadia Healthcare initiated with a Buy at UBS
09/20/21 Credit Suisse
Credit Suisse upgrades 'compelling' Acadia Healthcare on recent selloff
09/20/21 Credit Suisse
Acadia Healthcare upgraded to Outperform from Neutral at Credit Suisse
09/09/21 Cowen
Acadia Healthcare organic growth accelerating, says Cowen
ACHC Acadia Healthcare
$65.15 /

-0.33 (-0.50%)

Initiation
Encompass Health initiated with Buy, $98 target at UBS » 20:57
09/23/21
09/23
20:57
09/23/21
20:57
EHC

Encompass Health

$76.39 /

-0.4 (-0.52%)

UBS analyst Andrew Mok…

UBS analyst Andrew Mok initiated coverage of Encompass Health with a Buy rating and $98 price target. The analyst says Encompass represents one of the most compelling investments in his coverage with a "clear catalyst for value creation" when the company separates its home health and hospice business from its inpatient rehab business, likely in the next six months. He thinks it is appropriate to apply a sum-of-the-parts framework to the stock's valuation, which implies 30%-plus upside.

ShowHide Related Items >><<
EHC Encompass Health
$76.39 /

-0.4 (-0.52%)

EHC Encompass Health
$76.39 /

-0.4 (-0.52%)

09/23/21 UBS
Encompass Health initiated with a Buy at UBS
08/02/21 Raymond James
Encompass Health upgraded to Strong Buy from Outperform at Raymond James
08/02/21 Raymond James
Encompass Health upgraded to Strong Buy from Outperform at Raymond James
07/29/21 Deutsche Bank
Encompass Health price target raised to $110 from $104 at Deutsche Bank
EHC Encompass Health
$76.39 /

-0.4 (-0.52%)

EHC Encompass Health
$76.39 /

-0.4 (-0.52%)

Downgrade
Canadian National downgraded to In Line from Outperform at Evercore ISI » 20:56
09/23/21
09/23
20:56
09/23/21
20:56
CNI

Canadian National

$116.33 /

+1.33 (+1.16%)

Evercore ISI analyst…

Evercore ISI analyst Jonathan Chappell downgraded Canadian National to In Line from Outperform. The analyst notes that the chip shortage-induced auto production issues have a longer tail than previously assumed which, coupled with a soft grain harvest outlook and ongoing intermodal bottlenecks, are likely to pressure volumes through at least the end of 2021 and possibly into early 2022. Chappell adds that while he is positive on other transport stocks, the best case scenario for Canadian National is "fully priced in" following material outperformance resulting from activist interest and a very ambitious financial plan for 2022.

ShowHide Related Items >><<
CNI Canadian National
$116.33 /

+1.33 (+1.16%)

CNI Canadian National
$116.33 /

+1.33 (+1.16%)

09/23/21 Evercore ISI
Canadian National downgraded to In Line from Outperform at Evercore ISI
09/23/21 Goldman Sachs
Canadian National reinstated with a Neutral at Goldman Sachs
09/21/21 Desjardins
Canadian National price target raised to C$163 from C$162 at Desjardins
09/20/21 National Bank
Canadian National price target raised to C$151 from C$144 at National Bank
CNI Canadian National
$116.33 /

+1.33 (+1.16%)

CNI Canadian National
$116.33 /

+1.33 (+1.16%)

CNI Canadian National
$116.33 /

+1.33 (+1.16%)

CNI Canadian National
$116.33 /

+1.33 (+1.16%)

Downgrade
Canadian National downgraded to In Line from Outperform at Evercore ISI » 20:54
09/23/21
09/23
20:54
09/23/21
20:54
CNI

Canadian National

$116.33 /

+1.33 (+1.16%)

Evercore ISI analyst…

Evercore ISI analyst Jonathan Chappell downgraded Canadian National to In Line from Outperform with a $121 price target. The analyst views the shares fully priced after the outperformance resulting from activist interest and a "very ambitious" financial plan for 2022.

ShowHide Related Items >><<
CNI Canadian National
$116.33 /

+1.33 (+1.16%)

CNI Canadian National
$116.33 /

+1.33 (+1.16%)

09/23/21 Goldman Sachs
Canadian National reinstated with a Neutral at Goldman Sachs
09/21/21 Desjardins
Canadian National price target raised to C$163 from C$162 at Desjardins
09/20/21 National Bank
Canadian National price target raised to C$151 from C$144 at National Bank
09/20/21 Raymond James
Canadian National downgraded to Market Perform from Outperform at Raymond James
CNI Canadian National
$116.33 /

+1.33 (+1.16%)

CNI Canadian National
$116.33 /

+1.33 (+1.16%)

CNI Canadian National
$116.33 /

+1.33 (+1.16%)

CNI Canadian National
$116.33 /

+1.33 (+1.16%)

Hot Stocks
Zscaler to partner with TD Synnex » 20:33
09/23/21
09/23
20:33
09/23/21
20:33
ZS

Zscaler

$280.04 /

+2.28 (+0.82%)

TD SYNNEX "announced…

TD SYNNEX "announced a partnership with Zscaler which enables partners to purchase security solutions and services as part of the Zscaler Zero Trust Exchange platform directly from TD SYNNEX."

ShowHide Related Items >><<
ZS Zscaler
$280.04 /

+2.28 (+0.82%)

ZS Zscaler
$280.04 /

+2.28 (+0.82%)

09/10/21 Loop Capital
Zscaler price target raised to $280 from $250 at Loop Capital
09/10/21 BMO Capital
Zscaler price target raised to $315 from $250 at BMO Capital
09/10/21 Cowen
Zscaler price target raised to $314 from $255 at Cowen
09/10/21 Truist
Zscaler price target raised to $325 from $225 at Truist
ZS Zscaler
$280.04 /

+2.28 (+0.82%)

ZS Zscaler
$280.04 /

+2.28 (+0.82%)

ZS Zscaler
$280.04 /

+2.28 (+0.82%)

ZS Zscaler
$280.04 /

+2.28 (+0.82%)

Hot Stocks
Lancet publishes phase 3 trial data for Novavax NanoFlu vaccine » 20:26
09/23/21
09/23
20:26
09/23/21
20:26
NVAX

Novavax

$257.31 /

+25.1 (+10.81%)

Novavax "announced…

Novavax "announced publication of complete results from a pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M(TM) adjuvant, in The Lancet Infectious Diseases. The trial evaluated the immunogenicity and safety of NanoFlu in older adults compared to a leading U.S.-licensed quadrivalent influenza vaccine. In the complete analysis, NanoFlu was well-tolerated and produced significantly enhanced humoral and cellular immune responses versus the comparator vaccine. Novavax previously announced that NanoFlu achieved the trial's primary endpoints, demonstrating non-inferior immunogenicity to Fluzone(R) Quadrivalent against all four influenza virus strains included in the vaccine, while also showing both enhanced wild-type hemagglutination-inhibiting antibody responses against homologous strains and six heterologous A/H3N2 strains as compared to Fluzone Quadrivalent. Additionally, NanoFlu showed potent induction of polyfunctional antigen-specific CD4+ T-cells against A/H3N2 and B/Victoria strains, with a 126-189% increase in various post-vaccination cell-mediated immunity markers as compared to Fluzone Quadrivalent."

ShowHide Related Items >><<
NVAX Novavax
$257.31 /

+25.1 (+10.81%)

NVAX Novavax
$257.31 /

+25.1 (+10.81%)

09/08/21 Cantor Fitzgerald
Novavax combo vaccine could have 'differentiating' value, says Cantor Fitzgerald
08/30/21 B. Riley
Novavax is leader in making Covid-flu combination candidate, says B. Riley
08/04/21 Cantor Fitzgerald
Novavax EU deal suggests bottlenecks have been resolved, says Cantor Fitzgerald
06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
NVAX Novavax
$257.31 /

+25.1 (+10.81%)

NVAX Novavax
$257.31 /

+25.1 (+10.81%)

NVAX Novavax
$257.31 /

+25.1 (+10.81%)

NVAX Novavax
$257.31 /

+25.1 (+10.81%)

Hot Stocks
Innovent Biologics doses first patient in phase 2 trial of IBI112 » 20:21
09/23/21
09/23
20:21
09/23/21
20:21
IVBXF

Innovent Biologics

$10.00 /

+ (+0.00%)

Innovent Biologics…

Innovent Biologics "announced that the first patient with moderate-to-severe plaque psoriasis has been successfully dosed in a Phase 2 clinical trial of recombinant anti-interleukin 23p19 subunit antibody injection in China. Study CIBI112A201 is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 2 clinical trial, evaluating the efficacy and safety of IBI112 at different doses administered subcutaneously in the treatment of moderate-to-severe plaque psoriasis. The primary objective of the study is to evaluate the efficacy of subcutaneous injection of IBI112 at different doses in Chinese subjects with moderate-to-severe plaque psoriasis. The safety of drugs and the difference of administration interval between different therapeutic regimens will also be investigated, so as to provide dose information for Phase 3 clinical studies. This is also the first Phase 2 clinical study of domestic innovative drugs targeting IL-23p19, which is a significant milestone."

ShowHide Related Items >><<
IVBXF Innovent Biologics
$10.00 /

+ (+0.00%)

IVBXF Innovent Biologics
$10.00 /

+ (+0.00%)

11/03/20 Daiwa
Innovent Biologics initiated with a Buy at Daiwa
Hot Stocks
CVB Financial announces termination of 10b5-1 stock repurchase program » 19:41
09/23/21
09/23
19:41
09/23/21
19:41
CVBF

CVB Financial

$19.48 /

+0.43 (+2.26%)

CVB Financial announced…

CVB Financial announced that effective immediately it has terminated its 10b5-1 stock repurchase program in order to comply with Regulation M under the Securities Exchange Act of 1934, as amended. The termination is related to the announced acquisition by the Company and its principal subsidiary, Citizens Business Bank, of Suncrest Bank.

ShowHide Related Items >><<
CVBF CVB Financial
$19.48 /

+0.43 (+2.26%)

CVBF CVB Financial
$19.48 /

+0.43 (+2.26%)

Upgrade
Thermo Fisher upgraded to Conviction Buy from Buy at Goldman Sachs » 19:16
09/23/21
09/23
19:16
09/23/21
19:16
TMO

Thermo Fisher

$608.15 /

+1.15 (+0.19%)

Goldman Sachs analyst…

Goldman Sachs analyst Matthew Sykes upgraded Thermo Fisher to Conviction Buy from Buy with a price target of $690, up from $600. Sykes believes that Thermo Fisher's 3-turn valuation discount to the sector is "unwarranted", since the firm now has strong confidence the company can hit high single-digit growth. In addition, the analyst said the company is experiencing multiple growth drivers across their end markets and is organically building a "highly competitive" bioprocessing business experiencing strong growth rates at "highly" accretive margins.

ShowHide Related Items >><<
TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

09/23/21 Cowen
Thermo Fisher price target raised to $655 from $560 at Cowen
09/22/21 KeyBanc
Stevanato Group price target raised to $32 from $27 at KeyBanc
09/22/21 Benchmark
Thermo Fisher price target raised to $650 from $580 at Benchmark
09/22/21 BTIG
Thermo Fisher price target raised to $700 from $610 at BTIG
TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

Periodicals
IAC in talks to acquire Meredith in deal valued at over $2.5B, WSJ reports » 18:47
09/23/21
09/23
18:47
09/23/21
18:47
IAC

IAC

$133.72 /

+3.93 (+3.03%)

, MDP

Meredith

$44.92 /

+0.94 (+2.14%)

IAC/InterActiveCorp.…

IAC/InterActiveCorp. (IAC) is in advanced talks to buy Meredith (MDP), The Wall Street Journal's Jeffrey Trachtenberg reports, citing people familiar with the situation. The deal, which is expected to be valued at more than $2.5B, would vastly expand IAC's collection of online publications, which include Brides, Serious Eats and Investopedia, the people said. Reference Link

ShowHide Related Items >><<
MDP Meredith
$44.92 /

+0.94 (+2.14%)

IAC IAC
$133.72 /

+3.93 (+3.03%)

IAC IAC
$133.72 /

+3.93 (+3.03%)

08/24/21 Citi
IAC price target lowered to $175 from $185 at Citi
08/11/21 Wells Fargo
IAC price target lowered to $160 from $280 at Wells Fargo
08/06/21 Piper Sandler
IAC price target lowered to $158 from $180 at Piper Sandler
08/06/21 Wedbush
IAC price target lowered to $177 from $193 at Wedbush
MDP Meredith
$44.92 /

+0.94 (+2.14%)

08/17/21 Citi
Meredith price target raised to $54 from $51 at Citi
08/13/21 Benchmark
Meredith price target raised to $58 from $43 at Benchmark
06/29/21 Citi
Meredith price target raised to $51 from $41 at Citi
05/03/21 Barrington
Gray creates added scale with Meredith's broadcast assets, says Barrington
MDP Meredith
$44.92 /

+0.94 (+2.14%)

IAC IAC
$133.72 /

+3.93 (+3.03%)

MDP Meredith
$44.92 /

+0.94 (+2.14%)

IAC IAC
$133.72 /

+3.93 (+3.03%)

Hot Stocks
Nintendo unveils new 3D 'Kirby' title, new trailer for 'Bayonetta 3' » 18:40
09/23/21
09/23
18:40
09/23/21
18:40
NTDOY

Nintendo

$61.40 /

+0.78 (+1.29%)

, SQNXF

Square Enix

$58.00 /

-0.5 (-0.85%)

, CCOEY

Capcom

$14.82 /

-0.47 (-3.07%)

, PRXXF

Paradox Interactive

$18.26 /

+ (+0.00%)

At its Direct event,…

At its Direct event, Nintendo (NTDOY) made a number of new game announcements, Nintendo unveiled "Kirby and the Forgotten Land," out Spring 2022; a cloud version of "Dying Light 2" set to come to the console; more information on already announced titles "Metroid Dread," "Mario Party Superstars," "Splatoon 3," Square Enix's (SQNXF) "Triangle Strategy," and "Bayonetta 3"; new content updates "Mario Golf: Super Rush," "Animal Crossing: New Horizons," Capcom's (CCOEY) "Monster Hunter Rise," and "Hyrule Warriors Age of Calamity"; the "Castlevania Advance Collection" from Konami; a port of "Star Wars: Knights of the Old Republic"; and a "Shadowrun" trilogy release from Paradox (PRXXF).

ShowHide Related Items >><<
SQNXF Square Enix
$58.00 /

-0.5 (-0.85%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

CCOEY Capcom
$14.82 /

-0.47 (-3.07%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

08/02/21 Wedbush
Nintendo selloff may be overdone if OLED, Pokemon deliver, says Wedbush
07/07/21 Jefferies
Jefferies downgrades Nintendo to Hold with only 7% upside seen
07/06/21 Jefferies
Nintendo downgraded to Hold from Buy at Jefferies
05/21/21 Citi
Nintendo downgraded to Neutral from Buy at Citi
SQNXF Square Enix
$58.00 /

-0.5 (-0.85%)

07/21/21 Macquarie
Square Enix upgraded to Outperform from Neutral at Macquarie
02/04/21
Square Enix downgraded to Hold from Buy at Jefferies
CCOEY Capcom
$14.82 /

-0.47 (-3.07%)

PRXXF Paradox Interactive
$18.26 /

+ (+0.00%)

03/18/21 Jefferies
Paradox Interactive upgraded to Buy from Hold at Jefferies
02/25/21 Citi
Paradox Interactive price target lowered to SEK 200 from SEK 285 at Citi
12/11/20 Jefferies
Paradox Interactive downgraded to Hold from Buy at Jefferies
09/29/20 Jefferies
Paradox Interactive upgraded to Buy from Hold at Jefferies
NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

SQNXF Square Enix
$58.00 /

-0.5 (-0.85%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

CCOEY Capcom
$14.82 /

-0.47 (-3.07%)

SQNXF Square Enix
$58.00 /

-0.5 (-0.85%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

CCOEY Capcom
$14.82 /

-0.47 (-3.07%)

On The Fly
Fly Intel: After-Hours Movers » 18:35
09/23/21
09/23
18:35
09/23/21
18:35
AEHR

Aehr Test Systems

$11.77 /

-0.12 (-1.01%)

, PRGS

Progress Software

$46.18 /

+0.97 (+2.15%)

, TCOM

Trip.com Group

$29.34 /

+0.42 (+1.45%)

, COST

Costco

$452.00 /

-0.22 (-0.05%)

, GDYN

Grid Dynamics

$30.80 /

+0.85 (+2.84%)

, TMO

Thermo Fisher

$608.15 /

+1.15 (+0.19%)

, CAMP

CalAmp

$10.54 /

+0.48 (+4.77%)

, NKE

Nike

$159.50 /

+1.98 (+1.26%)

, MTN

Vail Resorts

$328.16 /

+6.66 (+2.07%)

, AIR

AAR Corp.

$33.20 /

+0.74 (+2.28%)

, ONTX

Onconova

$5.11 /

-1.215 (-19.22%)

, HLBZ

Helbiz

$22.87 /

-1.64 (-6.69%)

, INVH

Invitation Homes

$40.47 /

-0.07 (-0.17%)

Check out this evening's…

ShowHide Related Items >><<
TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

TCOM Trip.com Group
$29.34 /

+0.42 (+1.45%)

PRGS Progress Software
$46.18 /

+0.97 (+2.15%)

ONTX Onconova
$5.11 /

-1.215 (-19.22%)

NKE Nike
$159.50 /

+1.98 (+1.26%)

MTN Vail Resorts
$328.16 /

+6.66 (+2.07%)

INVH Invitation Homes
$40.47 /

-0.07 (-0.17%)

HLBZ Helbiz
$22.87 /

-1.64 (-6.69%)

GDYN Grid Dynamics
$30.80 /

+0.85 (+2.84%)

COST Costco
$452.00 /

-0.22 (-0.05%)

CAMP CalAmp
$10.54 /

+0.48 (+4.77%)

AIR AAR Corp.
$33.20 /

+0.74 (+2.28%)

AEHR Aehr Test Systems
$11.77 /

-0.12 (-1.01%)

AEHR Aehr Test Systems
$11.77 /

-0.12 (-1.01%)

08/26/21 Craig-Hallum
Aehr Test Systems price target raised to $12 from $5 at Craig-Hallum
07/16/21 Craig-Hallum
Aehr Test Systems price target raised to $5 from $3 at Craig-Hallum
PRGS Progress Software
$46.18 /

+0.97 (+2.15%)

08/06/21
Fly Intel: Top five analyst initiations
08/06/21 Citi
Progress Software initiated with a Neutral at Citi
07/14/21 Oppenheimer
Progress Software initiated with an Outperform at Oppenheimer
06/08/21 Guggenheim
Progress Software initiated with a Buy at Guggenheim
TCOM Trip.com Group
$29.34 /

+0.42 (+1.45%)

07/27/21 Mizuho
Mizuho says China's education crackdown won't carry over to other sectors
07/22/21 Mizuho
Baidu should be bought into results, says Mizuho
05/19/21 Mizuho
Trip.com Group price target raised to $50 from $45 at Mizuho
05/17/21
Fly Intel: Top five analyst upgrades
COST Costco
$452.00 /

-0.22 (-0.05%)

09/20/21 DA Davidson
DA Davidson sees less room for continued multiple expansion for Costco shares
09/09/21 Morgan Stanley
Costco price target raised to $500 from $425 at Morgan Stanley
09/02/21 Jefferies
Costco price target raised to $525 from $500 at Jefferies
09/02/21 DA Davidson
Costco reports 'another consistent comp' for August, says DA Davidson
GDYN Grid Dynamics
$30.80 /

+0.85 (+2.84%)

08/09/21 Northland
Grid Dynamics price target raised to $29 from $19 at Northland
08/06/21 Needham
Grid Dynamics price target raised to $30 from $23 at Needham
08/06/21 Canaccord
Grid Dynamics price target raised to $25 from $20 at Canaccord
07/30/21
Fly Intel: Top five analyst initiations
TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

09/23/21 Cowen
Thermo Fisher price target raised to $655 from $560 at Cowen
09/22/21 KeyBanc
Stevanato Group price target raised to $32 from $27 at KeyBanc
09/22/21 Benchmark
Thermo Fisher price target raised to $650 from $580 at Benchmark
09/22/21 BTIG
Thermo Fisher price target raised to $700 from $610 at BTIG
CAMP CalAmp
$10.54 /

+0.48 (+4.77%)

06/25/21 Canaccord
CalAmp continues to execute despite supply constraints, says Canaccord
04/23/21 Canaccord
CalAmp price target raised to $17 from $14 at Canaccord
03/18/21 Canaccord
CalAmp price target raised to $14 from $13 at Canaccord
12/18/20 JPMorgan
CalAmp downgraded to Underweight with $11 target at JPMorgan
NKE Nike
$159.50 /

+1.98 (+1.26%)

09/21/21 Citi
Citi survey shows Nike 'back in favor' with Chinese consumer
09/20/21 Deutsche Bank
Nike price target lowered to $171 from $179 at Deutsche Bank
09/20/21 Piper Sandler
Nike supply chain disruptions creates buying opportunity, says Piper Sandler
09/13/21
Fly Intel: Top five analyst downgrades
MTN Vail Resorts
$328.16 /

+6.66 (+2.07%)

09/21/21 Deutsche Bank
Vail Resorts price target raised to $301 from $298 at Deutsche Bank
09/20/21 KeyBanc
Vail Resorts upgraded to Overweight from Sector Weight at KeyBanc
06/08/21 BofA
Vail Resorts price target raised to $375 from $365 at BofA
06/08/21 Deutsche Bank
Vail Resorts price target raised to $298 from $294 at Deutsche Bank
AIR AAR Corp.
$33.20 /

+0.74 (+2.28%)

07/21/21 Canaccord
AAR Corp. results reflect steady aero recovery, says Canaccord
03/24/21 Benchmark
AAR Corp. price target raised to $52 from $40 at Benchmark
03/22/21 Canaccord
AAR Corp. price target raised to $48 from $40 at Canaccord
03/19/21 Truist
AAR Corp. price target raised to $50 from $41 at Truist
ONTX Onconova
$5.11 /

-1.215 (-19.22%)

05/18/21 Guggenheim
Onconova initiated with a Buy at Guggenheim
12/22/20 Noble Capital
Onconova upgraded to Outperform from Market Perform at Noble Capital
HLBZ Helbiz
$22.87 /

-1.64 (-6.69%)

INVH Invitation Homes
$40.47 /

-0.07 (-0.17%)

09/23/21 Deutsche Bank
Invitation Homes price target raised to $50 from $40 at Deutsche Bank
09/23/21 Goldman Sachs
Invitation Homes initiated with a Buy at Goldman Sachs
09/01/21 Barclays
Invitation Homes initiated with an Overweight at Barclays
08/17/21 B. Riley
Invitation Homes price target raised to $46 from $41 at B. Riley
TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

TCOM Trip.com Group
$29.34 /

+0.42 (+1.45%)

PRGS Progress Software
$46.18 /

+0.97 (+2.15%)

NKE Nike
$159.50 /

+1.98 (+1.26%)

MTN Vail Resorts
$328.16 /

+6.66 (+2.07%)

INVH Invitation Homes
$40.47 /

-0.07 (-0.17%)

GDYN Grid Dynamics
$30.80 /

+0.85 (+2.84%)

COST Costco
$452.00 /

-0.22 (-0.05%)

CAMP CalAmp
$10.54 /

+0.48 (+4.77%)

AIR AAR Corp.
$33.20 /

+0.74 (+2.28%)

AEHR Aehr Test Systems
$11.77 /

-0.12 (-1.01%)

  • 24
    Sep
  • 24
    Sep
  • 01
    Jul
  • 11
    Feb
TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

NKE Nike
$159.50 /

+1.98 (+1.26%)

COST Costco
$452.00 /

-0.22 (-0.05%)

TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

TCOM Trip.com Group
$29.34 /

+0.42 (+1.45%)

PRGS Progress Software
$46.18 /

+0.97 (+2.15%)

ONTX Onconova
$5.11 /

-1.215 (-19.22%)

NKE Nike
$159.50 /

+1.98 (+1.26%)

MTN Vail Resorts
$328.16 /

+6.66 (+2.07%)

HLBZ Helbiz
$22.87 /

-1.64 (-6.69%)

GDYN Grid Dynamics
$30.80 /

+0.85 (+2.84%)

COST Costco
$452.00 /

-0.22 (-0.05%)

CAMP CalAmp
$10.54 /

+0.48 (+4.77%)

AIR AAR Corp.
$33.20 /

+0.74 (+2.28%)

AEHR Aehr Test Systems
$11.77 /

-0.12 (-1.01%)

TMO Thermo Fisher
$608.15 /

+1.15 (+0.19%)

TCOM Trip.com Group
$29.34 /

+0.42 (+1.45%)

ONTX Onconova
$5.11 /

-1.215 (-19.22%)

NKE Nike
$159.50 /

+1.98 (+1.26%)

COST Costco
$452.00 /

-0.22 (-0.05%)

AEHR Aehr Test Systems
$11.77 /

-0.12 (-1.01%)

Hot Stocks
Nintendo announces expansion for Switch Online service, to include N64 games » 18:35
09/23/21
09/23
18:35
09/23/21
18:35
NTDOY

Nintendo

$61.40 /

+0.78 (+1.29%)

At its Direct event,…

At its Direct event, Nintendo made a number of new game and service announcements, including an expansion to its Nintendo Switch Online service that will include Nintendo 64 and Sega Genesis games. The expansion is set to launch in late October, and the company will offer compatible N64 and Genesis controllers for Switch.

ShowHide Related Items >><<
NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

08/02/21 Wedbush
Nintendo selloff may be overdone if OLED, Pokemon deliver, says Wedbush
07/07/21 Jefferies
Jefferies downgrades Nintendo to Hold with only 7% upside seen
07/06/21 Jefferies
Nintendo downgraded to Hold from Buy at Jefferies
05/21/21 Citi
Nintendo downgraded to Neutral from Buy at Citi
NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

Hot Stocks
Nintendo says animated 'Super Mario' film out holiday 2022 » 18:33
09/23/21
09/23
18:33
09/23/21
18:33
NTDOY

Nintendo

$61.40 /

+0.78 (+1.29%)

, CMCSA

Comcast

$56.15 /

+0.16 (+0.29%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

At its Nintendo Direct…

At its Nintendo Direct presentation, Nintendo (NTDOY) said that its animated "Mario" film made by NBCUniversal's (CMCSA) "Illumination," will release in theaters in holiday 2022, with a U.S. release date of December 21, 2022. The film will star Chris Pratt as Mario, Anya Taylor-Joy as Princess Peach, Charlie Days as Luigi, Jack Black as Bowser, Keegan-Michael Key as Toad, and Seth Rogen as Donkey Kong.

ShowHide Related Items >><<
NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

CMCSA Comcast
$56.15 /

+0.16 (+0.29%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

08/02/21 Wedbush
Nintendo selloff may be overdone if OLED, Pokemon deliver, says Wedbush
07/07/21 Jefferies
Jefferies downgrades Nintendo to Hold with only 7% upside seen
07/06/21 Jefferies
Nintendo downgraded to Hold from Buy at Jefferies
05/21/21 Citi
Nintendo downgraded to Neutral from Buy at Citi
CMCSA Comcast
$56.15 /

+0.16 (+0.29%)

09/20/21 Loop Capital
Loop Capital starts 'well-diversified' Comcast with Buy, $71 target
09/20/21 Loop Capital
Comcast initiated with a Buy at Loop Capital
09/14/21 KeyBanc
Comcast talked down Q3 internet net additions, says KeyBanc
07/30/21 Truist
Comcast price target raised to $70 from $65 at Truist
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
10/07/20 Benchmark
Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

CMCSA Comcast
$56.15 /

+0.16 (+0.29%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$56.15 /

+0.16 (+0.29%)

NTDOY Nintendo
$61.40 /

+0.78 (+1.29%)

CMCSA Comcast
$56.15 /

+0.16 (+0.29%)

CMCSA Comcast
$56.15 /

+0.16 (+0.29%)

Syndicate
Helbiz files to sell 11M shares of common stock » 18:32
09/23/21
09/23
18:32
09/23/21
18:32
HLBZ

Helbiz

$22.87 /

-1.64 (-6.69%)

The company states:…

The company states: "This prospectus relates to (i) the offer and sale of up to 5,750,000 share of Class A common stock that are issuable upon the exercise of warrants issued on November 21, 2019 to purchase shares of Class A Common Stockat an exercise price of $11.50 per share and (ii) the resale from time to time by the selling shareholders named in this prospectus of (a) 2,650,000 shares of Class A Common Stock and (b) up to 2,650,000 shares of Class A Common Stock that are issuable upon the exercise of warrants issued on August 12, 2021 to purchase shares of Class A Common Stock at an exercise price of $11.50 per share. We entered into a series of Subscription Agreements with the Selling Shareholders on August 12, 2021, by which the Selling Shareholders acquired the shares of Class A Common Stock and the right to acquire the PIPE Warrant Shares being offered pursuant to this prospectus. The Public Warrants were included in units that we offered in our initial public offering."

ShowHide Related Items >><<
HLBZ Helbiz
$22.87 /

-1.64 (-6.69%)

HLBZ Helbiz
$22.87 /

-1.64 (-6.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.